Mirati Therapeutics, Inc.
MRTX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $2,831,095 | $2,103,922 | $2,157,630 | $2,613,118 |
| - Cash | $258,718 | $129,866 | $241,925 | $235,260 |
| + Debt | $50,223 | $50,683 | $43,227 | $51,505 |
| Enterprise Value | $2,622,600 | $2,024,739 | $1,958,932 | $2,429,363 |
| Revenue | $16,400 | $13,690 | $7,167 | $934 |
| % Growth | 19.8% | 91% | 667.3% | – |
| Gross Profit | $13,857 | $12,407 | $6,350 | -$140,902 |
| % Margin | 84.5% | 90.6% | 88.6% | -15,085.9% |
| EBITDA | -$170,939 | -$186,163 | -$186,598 | -$207,523 |
| % Margin | -1,042.3% | -1,359.8% | -2,603.6% | -22,218.7% |
| Net Income | -$161,904 | -$176,913 | -$184,586 | -$202,475 |
| % Margin | -987.2% | -1,292.3% | -2,575.5% | -21,678.3% |
| EPS Diluted | -2.49 | -3.04 | -3.02 | -3.51 |
| % Growth | 18.1% | -0.7% | 14% | – |
| Operating Cash Flow | -$143,713 | -$131,400 | -$190,182 | -$128,800 |
| Capital Expenditures | -$36 | -$722 | -$269 | -$810 |
| Free Cash Flow | -$143,749 | -$132,122 | -$190,451 | -$129,610 |